The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features

Autoimmunity Reviews

Volumn 14, Issue 5, 2015, Pages 401-414

  Abreu, Mirhelen M ^a   Danowski, Adriana ^b   Wahl, Denis G ^c,d,e   Amigo, Mary Carmen ^f   Tektonidou, Maria ^g   Pacheco, Marcelo S ^b   Fleming, Norma ^h   Domingues, Vinicius ⁱ   Sciascia, Savino ^j,k   Lyra, Julia O ^l   Petri, Michelle ^m   Khamashta, Munther ⁿ   Levy, Roger A ^h  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Ophtalmology Service   (Brazil)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d Institut Lorrain du C ur et des Vaisseaux Louis Mathieu   (France)

^e INSERM UMR S 1116 University of Lorraine   (France)

^f AMERICAN BRITISH COWDRAY MEDICAL CENTER   (Mexico)

^g UNIVERSITY OF ATHENS   (Greece)

^h STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

ⁱ NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^j UNIVERSITY OF TURIN   (Italy)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l University Rio de Janeiro   (Brazil)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ ST THOMAS HOSPITAL   (United Kingdom)

more..

Author keywords

Accuracy; Antiphospholipid Syndrome; Clinical features; GRADE system; Non criteria manifestations

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CHOREA; CLINICAL FEATURE; GOLD STANDARD; HUMAN; LIVEDO RETICULARIS; MICROANGIOPATHY; MIGRAINE; MYELITIS; OUTCOME ASSESSMENT; SEIZURE; THROMBOCYTOPENIA; VALVULAR HEART DISEASE; VEIN THROMBOSIS; ANIMAL; IMMUNOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CHOREA; HUMANS; MYELITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84925141086     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.01.002     Document Type: Review

References (92)

1. Wilson W.A., Gharavi A.E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42:1309-1311.
2. Guyatt G.H., Oxman A.D., Vist G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336(7650):924-926.
3. Mendes de Abreu M., Wahl D., Levy R.A. The use of GRADE system on autoimmune diseases: challenges for shared decision-making. Lupus 2014, 23(12):1292-1294.
4. Guyatt G.H., Oxman A.D., Schünemann H.J., et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011, 64:380-382.
5. de Jesus G.R., Agmon-Levin N., Andrade C.A., et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. Autoimmun Rev 2014, 13(8):795-813.
6. Erkan D., Aguiar C.L., Andrade D., et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014, 13(6):685-696.
7. Cervera R., Rodríguez-Pintó I., Colafrancesco S., et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev 2014, 13(7):699-707.
8. Arnaud L., Mathian A., Devilliers H., Ruffatti A., Tektonidou M., Forastiero R., et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev 2014 Oct, 22(14):240-247. (pii: S1568-9972).
9. Cervera R., Piette J.C., Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46:1019-1027.
10. Zuily S., Regnault V., Guillemin F., Kaminsky P., Rat A.C., Lecompte T., et al. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. Thromb Res 2013, 132:e1-e7.
11. Leizorovicz A., Becker F., Buchmüller A., et al. Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study. Blood 2013, 122(10):1724-1729.
12. Reynaud Q., Lega J.C., Mismetti P., Chapelle C., Wahl D., Cathébras P., et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2014, 13(6):595-608.
13. Yang Y.J., Yun G.W., Song I.C., et al. Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia. Korean J Intern Med 2011, 26(4):449-454.
14. Kim K.J., Baek I.W., Yoon C.H., et al. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol 2013, 161(5):706-714.
15. Dasanu C.A., Codreanu I. Isolated thrombocytopenia: should we routinely screen for antiphospholipid antibodies?. Conn Med 2011, 75(5):281-284.
16. Diz-Kucukkaya R., Hacihanefioglu A., Yenerel M., et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001, 98:1760-1764.
17. Stasi R., Stipa E., Masi M., et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994, 84:4203-4208.
18. Cervera R., Boffa M.C., Khamashta M.A., Hughes G.R. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009, 18(10):889-893.
19. Italian Registry of Antiphospholipid Antibodies (IR-APA) Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Haematologica 1993, 78(5):313-318.
20. Cuadrado M.J., Mujic F., Muñoz E., et al. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis 1997, 56(3):194-196.
21. Stojanovich L., Kontic M., Djokovic A., et al. Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian national cohort study. Clin Exp Rheumatol 2013, 31(2). (234-4).
22. Comellas-Kirkerup L., Comellas-Kirkerup L., Hernández-Molina G., Cabral A.R. Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study. Blood 2010, 116(16). (3058-6).
23. Krause I., Blank M., Fraser A., et al. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology 2005, 210:749-754.
24. Erkan D., Lockshin M.D., APS ACTION members APS ACTION - AntiPhospholipid Syndrome Alliance For Clinical Trials and International Networking. Lupus 2012, 21(7):695-698.
25. Levy R.A., Jesús G.R.R. APS ACTION in Brazil. Braz J Rheumatol 2012, 52(5):813-814.
26. Cervera R., Tektonidou M.G., Espinosa G., et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus 2011, 20(2):165-167.
27. Nangaku M., Alpers C.E., Pippin J., et al. CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol 1998, 9(4):590-597.
28. Seshan S.V., Franzke C.W., Redecha P., et al. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood 2009, 114(8):1675-1683.
29. Wu L.H., Yu F., Tan Y., et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 2013, 83(4):715-723.
30. Amigo M.C., Garcia-Torres R., Robles M., et al. Renal involvement in primary antiphospholipid syndrome. J Rheumatol 1992, 19:1181-1185.
31. Nochy D., Daugas E., Droz D., et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 1999, 10:507-518.
32. Daugas E., Nochy D., du LT Huong, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002, 13:42-52.
33. Tektonidou M.G., Sotsiou F., Nakopoulou L., et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 2004, 50(8):7-2569.
34. Glueck H.I., Kant K.S., Weiss M.A., et al. Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants. Arch Intern Med 1985, 145:1389-1395.
35. Kant K.S., Pollak V.E., Weiss M.A., et al. Glomerular thrombosis in systemic lupus erythematosus. Prevalence and significance. Medicine 1981, 60:71-86.
36. Tektonidou M.G., Sotsiou F., Moutsopoulos H.M. Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary and systemic lupus erythematosus-related APS. J Rheumatol 2008, 35:1983-1988.
37. Song D., Wu L.H., Wang F.M., et al. The spectrum of thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 2013, 15:R1-R12.
38. Denas G., Jose S.P., Bracco A., Zoppellaro G., Pengo V. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 2014, 14:4-275. (pii: S1568-9972).
39. Petri M. Classification criteria for antiphospholipid syndrome: the case for cardiac valvular. J Rheumatol 2004, 31:2329-2330.
40. Hollan I., Meroni P.L., Ahearn J.M., Cohen Tervaert J.W., Curran S., Goodyear C.S., et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013, 12(10):1004-1015.
41. Espinola-Zavaleta N., Amigo M.C., Vargas-Barròn J., et al. Two and three-dimensional echocardiography in primary antiphospholipid syndrome: misdiagnosis as rheumatic valve disease. Lupus 2001, 10:511-513.
42. Bouillanne O., Millaire A., de Groote P., et al. Prevalence and clinical significance of antiphospholipid antibodies in heart valve disease: a case-control study. Am Heart J 1996, 132(4):790-795.
43. Kampolis C., Tektonidou M., Moyssakis I., et al. Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study. Semin Arthritis Rheum 2014, 43(4):558-565.
44. Stojanovich L., Markovic O., Marisavljevic D., et al. Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study. Lupus 2012, 21(3):4-338.
45. Krause I., Lev S., Fraser A., Blank M., Lorber M., Stojanovich L., et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 2005, 64(10):1490-1493.
46. Espinola-Zavaleta N., Montes R.M., Soto M.E., et al. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic follow-up study. J Rheumatol 2004, 31:2402-2407.
47. Amoroso A., Cacciapaglia F., De Castro S., et al. The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement. Clin Exp Rheumatol 2006, 24:287-294.
48. Roldan C.A., Qualls C.R., Sopko K.S., et al. Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study. J Rheumatol 2008, 35:224-229.
49. Mattos P., Santiago M.B. Association of antiphospholipid antibodies with valvulopathy in systemic lupus erythematosus: a systematic review. Clin Rheumatol 2011, 30(2):165-171.
50. Zuily S., Regnault V., Selton-Suty C., et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with SLE. Meta-analysis of echocardiographic studies. Circulation 2011, 124:215-222.
51. Diógenes M.J., Diógenes P.C., de Morais Carneiro R.M., et al. Cutaneous manifestations associated with antiphospholipid antibodies. Int J Dermatol 2004, 43(9):632-637.
52. Francès C., Niang S., Laffitte E., et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum 2005, 52(6):1785-1793.
53. Toubi E., Krause I., Fraser A., Lev S., Stojanovich L., Rovensky J., et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 2005, 23(4):499-504.
54. Krause I., Leibovici L., Blank M., et al. Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis. Lupus 2007, 16(3):176-180.
55. Gómez-Puerta J.A., Martin H., Amigo M.C., et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?. Medicine (Baltimore) 2005, 84(4):225-230.
56. García-Carrasco M., Galarza-Maldonado C., Gomez-Ponce M., et al. Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients. Lupus 2007, 16(5):366-367.
57. Mejía-Romero R., Garcia-Carrasco M., Galarza-Maldonado C., et al. Primary antiphospholipid syndrome in Latin American mestizo patients: clinical and immunologic characteristics and comparison with European patients. Clin Rheumatol 2008, 27(7):891-897.
58. Williams F.M., Cherkas L.F., Bertolaccini M.L., et al. Migraine and antiphospholipid antibodies: no association found in migraine-discordant monozygotic twins. Cephalalgia 2008, 28(10):1048-1052.
59. Cavestro C., Micca G., Molinari F., et al. Migraineurs show a high prevalence of antiphospholipid antibodies. J Thromb Haemost 2013, 9(7):1350-1354.
60. Asherson R.A., Derksen R.H., Harris E.N., et al. Chorea in systemic lupus erythematosus and "lupus-like" disease: association with antiphospholipid antibodies. Semin Arthritis Rheum 1987, 16(4):253-259.
61. Usugi T., Nakano K., Nakayama T., et al. Familial antiphospholipid antibody in a child with involuntary movement and deterioration. Pediatr Int 2007, 49(2):238-241.
62. Orzechowski N.M., Wolanskyj A.P., Ahlskog J.E., Kumar N., Moder K.G. Antiphospholipid antibody-associated chorea. J Rheumatol 2008, 35(11):2165-2170.
63. Reiner P., Galanaud D., Leroux G., et al. Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies. Mov Disord 2011, 26(13):2422-2427.
64. Verrot D., San-Marco M., Dravet C., et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997, 103(1):33-37.
65. Cimaz R., Romeo A., Scarano A., et al. Prevalence of anti-cardiolipin, anti-beta2 glycoprotein I, and anti-prothrombin antibodies in young patients with epilepsy. Epilepsia 2002, 43(1):52-59.
66. Peltola J.T., Haapala A., Isojärvi J.I., Auvinen A., Palmio J., Latvala K. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am J Med 2000, 109(9):712-717.
67. Liimatainen S., Peltola M., Sabater L., Fallah M., Kharazmi E., Haapala A.M., et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia 2010, 51(5):760-767.
68. Herranz M.T., Rivier G., Khamashta M.A., Blaser K.U., Hughes G.R. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994, 37(4):57-568.
69. Mackworth-Young C.G., Hughes G.R. Epilepsy: an early symptom of systemic lupus erythematosus. J Neurol Neurosurg Psychiatry 1985, 48(2):185.
70. Toubi E., Khamashta M.A., Panarra A., Hughes G.R. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995, 99(4):397-401.
71. Liou H.-H., Wang C.-R., Chen C.-J., et al. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus 1996, 5:307-312.
72. Kavassa F.B., Ioannidis J.P., Touloumi G., Boki K.A., Moutsopoulos H.M. Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM 2000, 93(3):169-174.
73. Mok C.C., Lau C.S., Wong R.W. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2001, 28:766-771.
74. Sanna G., Bertolaccini M.L., Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 2003, 12:935-942.
75. Appenzeller S., Cendes F., Costallat L.T.L. Epileptic seizures in systemic lupus erythematosus. Neurology 2004, 63:1808-1812.
76. Mikdashi J., Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology 2004, 43:1555-1560.
77. Sachse C., Lfithke K., Hartung K., et al. Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus, clinical and laboratory associations. Rheumatol Int 1995, 15:23-29.
78. Formiga F., Mitjavila F., Pac M., Moga I. Epilepsy and antiphospholipid antibodies in systemic lupus erythematosus patients. Lupus 1997, 6:486.
79. D'Cruz D.P., Mellor-Pita S., Joven B., Sanna G., Allanson J., Taylor J., et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 2004, 31(2):280-285.
80. Birnbaum J.L., Petri M., Thompson R., Izbudak I., Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum 2009, 60(11):3378-3387.
81. Pengo V., Banzato A., Denas G., Jose S.P., Bison E., Hoxha A., et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 2013, 12(8):832-834.
82. Roggenbuck D., Egerer K., von Landenberg P., Hiemann R., Feist E., Burmester G.R., et al. Antiphospholipid antibody profiling: time for a new technical approach?. Autoimmun Rev 2012, 11(11):821-826.
83. Hughes G.R.V., Khamashta M.A. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003, 62:1127.
84. Jawad A.S.M. Classification vs diagnostic criteria - a revised international consensus statement on classification criteria for APS is required to accommodate the seronegative clinical entity. Ann Rheum Dis 2004, 5:608.
85. Mahler M., Norman G.L., Meroni P.L., Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012, 12(2):313-317.
86. Meijide H., Sciascia S., Sanna G., Khamashta M.A., Bertolaccini M.L. The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev 2013, 12(3):421-425.
87. Bertolaccini M.L., Amengual O., Andreoli L., et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014, 13(8):917-930.
88. Cervera R., Conti F., Doria A., et al. Does seronegative antiphospholipid syndrome really exist?. Autoimmun Rev 2012, 11:581-584.
89. Rodriguez-Garcia J.L., Bertolaccini M.L., Cuadrado M.J., Sanna G., Ateka-Barrutia O., Khamashta M.A. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS'). Ann Rheum Dis 2012, 71(2):242-244.
90. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus 2010, 19:419-423.
91. Salcido-Ochoa F., Cabiedes Alarcón-Segovia D., Cabral A.R. Antiprothrombin Antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. J Clin Rheumatol 2002, 8(5):251-255.
92. Conti F., Alessandri C., Sorice M., et al. Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome. Clin Exp Immunol 2012, 167(3):429-437.